ATE531789T1 - Zellmembranenveränderung - Google Patents
ZellmembranenveränderungInfo
- Publication number
- ATE531789T1 ATE531789T1 AT01984107T AT01984107T ATE531789T1 AT E531789 T1 ATE531789 T1 AT E531789T1 AT 01984107 T AT01984107 T AT 01984107T AT 01984107 T AT01984107 T AT 01984107T AT E531789 T1 ATE531789 T1 AT E531789T1
- Authority
- AT
- Austria
- Prior art keywords
- cell membrane
- regulation
- membrane changes
- proteins
- sequences
- Prior art date
Links
- 210000000170 cell membrane Anatomy 0.000 title abstract 2
- 108090000623 proteins and genes Proteins 0.000 abstract 2
- 102000004169 proteins and genes Human genes 0.000 abstract 2
- 108091029865 Exogenous DNA Proteins 0.000 abstract 1
- 108091028043 Nucleic acid sequence Proteins 0.000 abstract 1
- 230000006907 apoptotic process Effects 0.000 abstract 1
- 210000004027 cell Anatomy 0.000 abstract 1
- 230000003828 downregulation Effects 0.000 abstract 1
- 230000000694 effects Effects 0.000 abstract 1
- 238000001415 gene therapy Methods 0.000 abstract 1
- 210000000987 immune system Anatomy 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
- 238000012986 modification Methods 0.000 abstract 1
- 230000004048 modification Effects 0.000 abstract 1
- 230000002085 persistent effect Effects 0.000 abstract 1
- 229920001184 polypeptide Polymers 0.000 abstract 1
- 102000004196 processed proteins & peptides Human genes 0.000 abstract 1
- 108090000765 processed proteins & peptides Proteins 0.000 abstract 1
- 230000003827 upregulation Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/52—Cytokines; Lymphokines; Interferons
- C07K14/54—Interleukins [IL]
- C07K14/55—IL-2
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/20—Interleukins [IL]
- A61K38/2013—IL-2
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/001—Preparations to induce tolerance to non-self, e.g. prior to transplantation
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/461—Cellular immunotherapy characterised by the cell type used
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/462—Cellular immunotherapy characterized by the effect or the function of the cells
- A61K39/4621—Cellular immunotherapy characterized by the effect or the function of the cells immunosuppressive or immunotolerising
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/462—Cellular immunotherapy characterized by the effect or the function of the cells
- A61K39/4622—Antigen presenting cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
- A61K39/4643—Vertebrate antigens
- A61K39/46434—Antigens related to induction of tolerance to non-self
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
- A61K47/66—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid the modifying agent being a pre-targeting system involving a peptide or protein for targeting specific cells
- A61K47/665—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid the modifying agent being a pre-targeting system involving a peptide or protein for targeting specific cells the pre-targeting system, clearing therapy or rescue therapy involving biotin-(strept) avidin systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
- A61K47/6901—Conjugates being cells, cell fragments, viruses, ghosts, red blood cells or viral vectors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B82—NANOTECHNOLOGY
- B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
- B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
- C07K14/36—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Actinomyces; from Streptomyces (G)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/52—Cytokines; Lymphokines; Interferons
- C07K14/525—Tumour necrosis factor [TNF]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70575—NGF/TNF-superfamily, e.g. CD70, CD95L, CD153, CD154
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/0006—Modification of the membrane of cells, e.g. cell decoration
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/0081—Purging biological preparations of unwanted cells
- C12N5/0087—Purging against subsets of blood cells, e.g. purging alloreactive T cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K2035/122—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells for inducing tolerance or supression of immune responses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/515—Animal cells
- A61K2039/5156—Animal cells expressing foreign proteins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
- A61K2239/26—Universal/off- the- shelf cellular immunotherapy; Allogenic cells or means to avoid rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
- A61K2239/31—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterized by the route of administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
- A61K2239/38—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterised by the dose, timing or administration schedule
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S530/00—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof
- Y10S530/81—Carrier - bound or immobilized peptides or proteins and the preparation thereof, e.g. biological cell or cell fragment as carrier
- Y10S530/812—Peptides or proteins is immobilized on, or in, an organic carrier
- Y10S530/815—Carrier is a synthetic polymer
- Y10S530/816—Attached to the carrier via a bridging agent
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Medicinal Chemistry (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Immunology (AREA)
- Cell Biology (AREA)
- Zoology (AREA)
- Genetics & Genomics (AREA)
- Epidemiology (AREA)
- Molecular Biology (AREA)
- Microbiology (AREA)
- Biochemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biotechnology (AREA)
- Biophysics (AREA)
- Gastroenterology & Hepatology (AREA)
- Wood Science & Technology (AREA)
- Biomedical Technology (AREA)
- Mycology (AREA)
- General Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Toxicology (AREA)
- Hematology (AREA)
- Nanotechnology (AREA)
- Transplantation (AREA)
- Medical Informatics (AREA)
- Oncology (AREA)
- Crystallography & Structural Chemistry (AREA)
- Virology (AREA)
- Communicable Diseases (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US21558000P | 2000-06-30 | 2000-06-30 | |
PCT/US2001/020946 WO2002002751A2 (en) | 2000-06-30 | 2001-07-02 | Alteration of cell membrane |
Publications (1)
Publication Number | Publication Date |
---|---|
ATE531789T1 true ATE531789T1 (de) | 2011-11-15 |
Family
ID=22803538
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
AT01984107T ATE531789T1 (de) | 2000-06-30 | 2001-07-02 | Zellmembranenveränderung |
Country Status (7)
Country | Link |
---|---|
US (4) | US7238360B2 (de) |
EP (1) | EP1299522B1 (de) |
JP (1) | JP2004524806A (de) |
AT (1) | ATE531789T1 (de) |
AU (2) | AU2002216763B2 (de) |
CA (1) | CA2413237C (de) |
WO (1) | WO2002002751A2 (de) |
Families Citing this family (18)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7927602B2 (en) * | 2002-07-23 | 2011-04-19 | University Of Louisville Research Foundation, Inc. | Fas ligand-avidin/streptavidin fusion proteins |
AU2002216763B2 (en) | 2000-06-30 | 2007-03-01 | University Of Louisville Research Foundation, Inc. | Alteration of cell membrane |
AU2003240281A1 (en) * | 2002-06-14 | 2003-12-31 | Case Western Reserve University | Cell targeting methods and compositions |
US7373559B2 (en) * | 2003-09-11 | 2008-05-13 | Copan Systems, Inc. | Method and system for proactive drive replacement for high availability storage systems |
WO2006119121A2 (en) * | 2005-04-29 | 2006-11-09 | University Of Louisville Research Foundation, Inc. | Cell-surface decoration with active agents |
CA2981431C (en) | 2005-06-08 | 2021-04-13 | Dana-Farber Cancer Institute Inc. | Use of compounds that reduce activity or expression of programmed cell death-1 to treat lymphoma |
KR20080090413A (ko) * | 2005-12-08 | 2008-10-08 | 유니버시티 오브 루이빌 리서치 파운데이션, 인코포레이티드 | T 조절 세포의 확장을 위한 방법 및 조성물 |
AU2006321888A1 (en) * | 2005-12-08 | 2007-06-14 | University Of Louisville Research Foundation, Inc. | Immunostimulatory compositions and methods |
US10407672B2 (en) * | 2006-03-27 | 2019-09-10 | Seattle Children's Hospital | Compositions and methods comprising the use of cell surface displayed homing endonucleases |
EP2133365B1 (de) * | 2006-12-27 | 2017-05-17 | Emory University | Zusammensetzungen und Verfahren zur Behandlung von Infektionen und Tumoren |
HUE028582T2 (en) * | 2008-11-28 | 2016-12-28 | Univ Emory | Method for determining the efficacy of PD-1 antagonists |
US9624469B2 (en) | 2010-07-22 | 2017-04-18 | Cellect Biotherapeutics Ltd. | Regulatory immune cells with enhanced targeted cell death effect |
US12023367B2 (en) | 2015-06-19 | 2024-07-02 | University Of Louisville Research Foundation, Inc. | Immunomodulation for the long term prevention and treatment of autoimmune diseases and foreign tissue rejection |
US10906951B2 (en) | 2015-07-29 | 2021-02-02 | Onk Therapeutics Limited | Modified natural killer cells and natural killer cell lines having increased cytotoxicity |
ES2939084T3 (es) | 2015-07-29 | 2023-04-18 | Onk Therapeutics Ltd | Células asesinas naturales y líneas de células asesinas naturales modificadas que tienen citotoxicidad aumentada |
PT3592392T (pt) * | 2017-03-10 | 2023-11-23 | Georgia Tech Res Inst | Biomateriais manipulados por fasl com função imunomoduladora |
US11591718B2 (en) | 2018-04-27 | 2023-02-28 | Aimed Bio Inc. | Magnetic-based biopanning method through attachment of magnetic bead to cell |
US11504335B2 (en) | 2018-06-18 | 2022-11-22 | University Of Kentucky Research Foundation | Increased cell retention in diseased site when cells encapsulated in gelatin methacrylate and polyethylene glycol diacrylate hydrogels |
Family Cites Families (20)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH04501808A (ja) * | 1989-07-06 | 1992-04-02 | セラジェン・インコーポレーテッド | ハイブリッド分子 |
US6071716A (en) * | 1990-10-01 | 2000-06-06 | Dana-Farber Cancer Institute | DNA encoding, B7, a new member of the IG superfamily with unique expression on activated and neoplastic B cells |
US5470701A (en) * | 1993-02-24 | 1995-11-28 | The Regents Of The University Of California | Method for determining favorable prognosis in an HIV positive subject using HLA-DR+ /CD38- CD8bright cells |
US5858776A (en) * | 1993-11-03 | 1999-01-12 | Repligen Corporation | Tumor cells with increased immunogenicity and uses therefor |
US6130316A (en) * | 1993-07-26 | 2000-10-10 | Dana Farber Cancer Institute | Fusion proteins of novel CTLA4/CD28 ligands and uses therefore |
US6218510B1 (en) * | 1994-03-02 | 2001-04-17 | Brigham & Woman's Hospital | B7-1 and B7-2 polypeptides |
JP4435304B2 (ja) * | 1995-06-29 | 2010-03-17 | イミュネックス・コーポレーション | アポトーシスを誘導するサイトカイン |
JP2001520636A (ja) * | 1995-08-30 | 2001-10-30 | ザ リージェンツ オブ ザ ユニバーシティー オブ カリフォルニア | 慢性炎症性疾患における細胞蓄積の治療 |
GB9523469D0 (en) | 1995-11-16 | 1996-01-17 | Sandoz Ltd | Organic compounds |
WO1997033617A1 (en) | 1996-03-13 | 1997-09-18 | Protein Design Labs, Inc. | Fas ligand fusion proteins and their uses |
US6060054A (en) | 1996-04-10 | 2000-05-09 | National Jewish Medical And Research Center | Product for T lymphocyte immunosuppression |
US6042826A (en) * | 1996-11-15 | 2000-03-28 | Health Research, Inc. | Method for inducing apoptosis of primary central nervous system B cell lymphomas |
GB9721075D0 (en) | 1997-10-03 | 1997-12-03 | Cancer Res Campaign Tech | Materials and methods relating to the stimulation of cells |
US7144991B2 (en) | 1999-06-07 | 2006-12-05 | Aletheon Pharmaceuticals, Inc. | Streptavidin expressed gene fusions and methods of use thereof |
AU783996B2 (en) | 1999-12-16 | 2006-01-12 | University Of Louisville Research Foundation, Inc. | Compositions and methods for caspase-induced apoptosis |
US7927602B2 (en) | 2002-07-23 | 2011-04-19 | University Of Louisville Research Foundation, Inc. | Fas ligand-avidin/streptavidin fusion proteins |
EP1250055B1 (de) | 2000-01-24 | 2010-09-15 | University Of Louisville Research Foundation, Inc. | Immunmodulation mit rezeptorinduziertem tod durch apoptosis |
AU2002216763B2 (en) | 2000-06-30 | 2007-03-01 | University Of Louisville Research Foundation, Inc. | Alteration of cell membrane |
KR20080090413A (ko) | 2005-12-08 | 2008-10-08 | 유니버시티 오브 루이빌 리서치 파운데이션, 인코포레이티드 | T 조절 세포의 확장을 위한 방법 및 조성물 |
AU2006321888A1 (en) | 2005-12-08 | 2007-06-14 | University Of Louisville Research Foundation, Inc. | Immunostimulatory compositions and methods |
-
2001
- 2001-07-02 AU AU2002216763A patent/AU2002216763B2/en not_active Ceased
- 2001-07-02 JP JP2002507992A patent/JP2004524806A/ja active Pending
- 2001-07-02 CA CA2413237A patent/CA2413237C/en not_active Expired - Fee Related
- 2001-07-02 US US10/312,245 patent/US7238360B2/en not_active Expired - Lifetime
- 2001-07-02 AU AU1676302A patent/AU1676302A/xx active Pending
- 2001-07-02 WO PCT/US2001/020946 patent/WO2002002751A2/en active IP Right Grant
- 2001-07-02 EP EP01984107A patent/EP1299522B1/de not_active Expired - Lifetime
- 2001-07-02 AT AT01984107T patent/ATE531789T1/de active
-
2007
- 2007-06-25 US US11/819,080 patent/US8076096B2/en not_active Expired - Fee Related
-
2011
- 2011-12-12 US US13/316,915 patent/US8728747B2/en not_active Expired - Fee Related
-
2014
- 2014-05-19 US US14/280,940 patent/US9255133B2/en not_active Expired - Fee Related
Also Published As
Publication number | Publication date |
---|---|
EP1299522B1 (de) | 2011-11-02 |
US7238360B2 (en) | 2007-07-03 |
WO2002002751A2 (en) | 2002-01-10 |
US9255133B2 (en) | 2016-02-09 |
JP2004524806A (ja) | 2004-08-19 |
US20090074870A1 (en) | 2009-03-19 |
AU2002216763B2 (en) | 2007-03-01 |
US20120213730A1 (en) | 2012-08-23 |
AU1676302A (en) | 2002-01-14 |
US20150086506A1 (en) | 2015-03-26 |
WO2002002751A3 (en) | 2002-10-03 |
US20030219419A1 (en) | 2003-11-27 |
CA2413237A1 (en) | 2002-01-10 |
EP1299522A2 (de) | 2003-04-09 |
US8076096B2 (en) | 2011-12-13 |
US8728747B2 (en) | 2014-05-20 |
CA2413237C (en) | 2013-09-10 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
ATE531789T1 (de) | Zellmembranenveränderung | |
DK1210411T3 (da) | Sammensætninger og fremgangsmåder til forbedret celledyrkning | |
AU4981101A (en) | Subtilisin variants | |
WO2000066753A3 (en) | Modified vitamin k-dependent polypeptides | |
DK1650307T3 (da) | Fremgangsmåde til fremstilling af rekombinante proteiner ved anvendelse af apoptoseinhibitorer | |
ATE299185T1 (de) | Hemmung der expression von genen mittels dsrna | |
AP2000001811A0 (en) | Modified vitamin K- dependent polypeptides. | |
ATE472334T1 (de) | Polypeptidsequenzen, die an der modulation des immunsupppressiven effekts viraler proteine beteiligt sind | |
FI932678A0 (fi) | Pao alfavirus baserande DNA expressionssystem | |
DE69942459D1 (de) | Isolierte nukleinsäuremoleküle die t-zellen induzierbare faktoren kodieren (tif), kodierte proteine und ihre anwendung | |
NO990086L (no) | Avkortete, l°selige tumornekrosefaktorreseptorer av type I og type II | |
CY1108459T1 (el) | Ακτ-3 νουκλεϊκα οξεα, πολυπεπτιδια, και χρησεις αυτων | |
WO2002006457A3 (en) | Novel lipase genes | |
DE60043428D1 (de) | POLYPEPTIDE MIT VERZWEIGUNGSENZYM-AKTIVITäT UND FüR DIESE KODIERENDE NUKLEINSäUREN | |
ATE326537T1 (de) | Schnell erzeugung von stabilen säugertier- zellinien mit gewinnung eines hohen gehalts von recombinanten proteine | |
DE69928395D1 (de) | Cyclin-e2 proteine und dafür kodierende gene | |
MXPA04001720A (es) | Acido nucleicos bv8 y polipeptidos con actividad mitogenica. | |
PT1140023E (pt) | Formulacoes cocleares integrativas de proteina-adn e metodos de transformacao celular | |
DK0984983T3 (da) | Modulatorer af intracellulære inflammations-, celledöds- og celleoverlevelsesforlöb indeholdende et CARD- og et kinasedomæne | |
PT1062336E (pt) | Moduladores da funcao de receptores da familia dos receptores tnf/ngf e outras proteinas | |
AR010744A1 (es) | Inhibidores polipropilos de ciclofilina | |
ATE240349T1 (de) | Peptide zur inhibierung von hpv e6-proteinen | |
EA200401390A1 (ru) | N-ацетилглюкозамин-6-фосфатдеацетилаза человека, взаимодействующая с каспазой-8, и способы ее применения | |
WO2002014369A3 (en) | Human kininogen d5 domain polypeptides and their use | |
BR0108187A (pt) | Moléculas trade e usos relacionados com as mesmas |